Prediabetes in End Stage Renal Disease on Dialysis

January 4, 2026 updated by: Hany Ahmed Mohamed, Sohag University

Screening of Prediabetes in End Stage Renal Disease on Dialysis

Prediabetes is a highly prevalent condition, affecting about one-third of adults in the United States Patients with prediabetes have an increased risk for diabetes, with 2% to 10% progressing to diabetes each yea Although prediabetes is frequently considered an intermediary stage in the progression between normoglycemia and diabetes, many individuals may have prediabetes for several years, while some may never progress.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

262

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Sohag, Egypt
        • Sohag University .Faculty of Medicine
    • Egypt
      • Sohag, Egypt, Egypt, 82525
        • Faculty of medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population is defined as adult patients (aged 18 years or older) with End-Stage Renal Disease (ESRD) who are currently on dialysis.

This population will be recruited from a single center: Sohag Faculty of Medicine, Sohag University, Egypt.

Description

Inclusion Criteria:

  • End stage renal disease on dialysis patients aged ≥ 18 years old.

Exclusion Criteria:

  1. Patients previously diagnosed with prediabetes.
  2. Patients previously diagnosed with diabetes mellitus.
  3. Acute Medical Status :Hospitalized patients.
  4. Physiological States: Pregnant females.Lactating females.
  5. Specific Comorbidities & Conditions: Polycystic kidney disease.
  6. New York Heart Association (NYHA) class III or IV heart failure.
  7. Known liver cirrhosis. or HIV/AIDS.
  8. Renal cancer.
  9. Active immunosuppression. or Recent chemotherapy or immunosuppressive therapy.
  10. History of organ transplantation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The prevalence of prediabetes in the End Stage Renal Disease (ESRD) on dialysis cohort.
Time Frame: "The time frame for measurement of the primary outcome (prevalence of prediabetes) with all diagnostic measurements (Fasting Plasma Glucose mg/dl) performed once per participant at the time of their inclusion in the study."
"The time frame for measurement of the primary outcome (prevalence of prediabetes) with all diagnostic measurements (Fasting Plasma Glucose mg/dl) performed once per participant at the time of their inclusion in the study."

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 13, 2025

Primary Completion (Actual)

September 13, 2025

Study Completion (Actual)

October 12, 2025

Study Registration Dates

First Submitted

January 4, 2026

First Submitted That Met QC Criteria

January 4, 2026

First Posted (Actual)

January 13, 2026

Study Record Updates

Last Update Posted (Actual)

January 13, 2026

Last Update Submitted That Met QC Criteria

January 4, 2026

Last Verified

April 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-25-4--6PD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Screening

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe